{
    "clinical_study": {
        "@rank": "122657", 
        "arm_group": [
            {
                "arm_group_label": "BI 691751 dose 2 (part I)", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "BI 691751 dose 3 (part I)", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "BI 691751 dose 4 (part I)", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "BI 691751 dose 5 (part I)", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "BI 691751 dose 6 (part I)", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "BI 691751 dose 7 (part I)", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "BI 691751dose 1 (part I)", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "Placebo (part I)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo solution"
            }, 
            {
                "arm_group_label": "BI 691751 tablet (part II)", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as 1 tablet"
            }, 
            {
                "arm_group_label": "BI 691751 solution (part II)", 
                "arm_group_type": "Active Comparator", 
                "description": "single dose given as oral solution"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of  single\n      rising doses of BI 691751 in healthy male subjects  (part I).\n\n      To investigate  the relative bioavailability of BI 691751 given as tablet versus oral\n      solution (part II)"
        }, 
        "brief_title": "Safety of Single Rising Doses and Relative Bioavailability of BI 691751", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy male subjects\n\n          2. Subjects must be able to understand and comply with study requirements\n\n          3. Age from 18 to 55 years\n\n          4. BMI range: from 18.5 to 29.9 kg/m2\n\n          5. Known genotype as specified in the study protocol\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01843972", 
            "org_study_id": "1334.1", 
            "secondary_id": "2012-005721-67"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 691751 dose 6 (part I)", 
                "description": "oral solution BI 691751, dose 6", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 solution (part II)", 
                "description": "oral solution", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (part I)", 
                "description": "placebo solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 dose 2 (part I)", 
                "description": "oral solution BI 691751, dose 2", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 dose 5 (part I)", 
                "description": "oral solution BI 691751, dose 5", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 tablet (part II)", 
                "description": "1 tablet", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 dose 3 (part I)", 
                "description": "oral solution BI 691751, dose 3", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 dose 4 (part I)", 
                "description": "oral solution BI 69175, dose 4", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 dose 7 (part I)", 
                "description": "oral solution BI 691751, dose 7", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751dose 1 (part I)", 
                "description": "oral solution BI 69175, dose 1", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1334.1.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "10", 
        "official_title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BI 691751 in Healthy Male Volunteers in a Randomised, Single-blind, Placebo-controlled Design (Part I) and Investigation of Relative Bioavailability of BI 691751 Given as Tablet and Oral Solution to Healthy Male Subjects in an Open, Randomised, Single-dose, Single Period Parallel Group Design (Part II).", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-72h (area under the concentration-time curve of the analyte of BI 691751 in plasma over the time interval from 0 to 72 h) (part II)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours postdose"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte of BI 691751 in plasma) (part II)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours postdose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01843972"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax (maximum measured concentration of BI 691751 in plasma) (part I)", 
                "safety_issue": "No", 
                "time_frame": "up to 240 hours postdose"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 extrapolated to infinity) (part I)", 
                "safety_issue": "No", 
                "time_frame": "up to 240 hours postdose"
            }, 
            {
                "measure": "AUC0-tz (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 up to the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "up to 240 hours postdose"
            }, 
            {
                "measure": "t1/2 (terminal half-life of the analyte of BI 691751 in plasma) (part I)", 
                "safety_issue": "No", 
                "time_frame": "up to 240 hours postdose"
            }, 
            {
                "measure": "tmax (time from dosing to maximum measured concentration of BI 691751) (part I)", 
                "safety_issue": "No", 
                "time_frame": "up to 240 hours postdose"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}